LU
Lundbeck
LUN.CO·CPSECopenhagen DKFounded 19155,600 employees
Mid CappharmaPublicCNSNeurology
Platform: CNS Specialty
Market Cap
$8B
All Drugs
4
Clinical Trials
8
Failed / Terminated
3
FDA Approved
1
Stock Price & Catalysts (LUN.CO)
Loading LUN.CO stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Lisonesiran | LUN-7917 | Phase 2 | 2 | PRMT5 | CTCLMS | ||
| Sovarapivir | LUN-4030 | Preclinical | 1 | Cl18.2 | EoETTR Amyloidosis | ||
| Gelicapivasertib | LUN-8561 | Approved | 4 | Aβ | Epilepsy | ||
| Pemizumab | LUN-6452 | Phase 1 | 1 | TROP-2 | UCMM |
SEC Filings & Financial Documents
SEC filings are not available for CPSE-listed companies.
Lundbeck trades on CPSE (DK). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (9)